Apremilast or Biologics (IL-17/IL-23 Inhibitors) Are the Preferred Systemic Treatments for Psoriasis with Elevated Liver Enzymes
For patients with psoriasis and elevated AST/ALT, apremilast is the safest first-line systemic option as it requires no routine laboratory monitoring and is metabolized without hepatotoxicity risk, while biologics (particularly IL-17 and IL-23 inhibitors) are excellent alternatives that do not cause liver damage. 1, 2, 3
Why Apremilast Is Ideal in This Setting
Apremilast stands out because:
- No hepatotoxicity: It is metabolized via cytochrome P450 without causing liver damage 1
- No routine lab monitoring required: The AAD-NPF guidelines explicitly state that "routine laboratory screening and monitoring can be considered on an individual basis" - meaning it's optional, not mandatory 1
- Real-world safety data: A 2025 study of 841 psoriasis patients with serious baseline comorbidities, including liver disease, showed apremilast was safe with no increased adverse events 3
- Proven efficacy in liver disease: A 2025 case report demonstrated successful treatment of psoriasis coexisting with primary sclerosing cholangitis using apremilast, achieving complete clearance with stable liver function 4
Dosing: Start with the standard titration schedule up to 30 mg twice daily 1
Biologics as Excellent Alternatives
IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab) are highly effective and safe in patients with elevated LFTs:
- A 2025 real-world study of 278 patients showed that those with elevated baseline LFTs who received secukinumab, ixekizumab, or adalimumab experienced significant decreases in liver enzymes over 6 months rather than worsening 2
- These patients achieved similar PASI-75 response rates and drug survival as those with normal baseline LFTs 2
- The study concluded these biologics present "an opportunity rather than a risk" for patients with elevated LFTs 2
What to AVOID
Methotrexate - Use with Extreme Caution or Avoid
While recent evidence suggests methotrexate's hepatotoxicity may be overstated, it remains problematic in patients with pre-existing liver dysfunction:
- A 2026 systematic review confirms MTX hepatotoxicity is "patient-specific rather than inherent to the drug" but identifies obesity, diabetes, and pre-existing liver disease as key risk factors 5
- A 2024 study showed psoriasis patients already have elevated FIB-4 scores indicating increased liver fibrosis risk 6
- If MTX must be used, more frequent monitoring is essential in patients with liver disease 7
Cyclosporine - Requires Caution
The AAD-NPF guidelines note that patients with liver disease taking cyclosporine may require closer monitoring of drug levels 1. However, cyclosporine is primarily nephrotoxic rather than hepatotoxic, and a 2026 case report showed successful use in a patient with autoimmune hepatitis 8. Still, it's not the optimal first choice.
Acitretin - Acceptable but Less Ideal
Acitretin is not immunosuppressive and can be used, but it does require monitoring of liver function tests 1. The British guidelines note that combining acitretin with methotrexate increases hepatotoxicity risk 7.
Practical Algorithm
For psoriasis with elevated AST/ALT:
- First-line: Apremilast (if moderate psoriasis, patient accepts slower onset)
- First-line: IL-17 or IL-23 inhibitor biologics (if severe psoriasis, need rapid clearance)
- Second-line: TNF inhibitors (etanercept, adalimumab) - also safe per real-world data 2, 9
- Avoid or use with intensive monitoring: Methotrexate
- Use with caution: Cyclosporine (monitor drug levels), Acitretin (monitor LFTs)
Critical Pitfall to Avoid
Do not withhold systemic therapy due to elevated LFTs alone. The 2025 study explicitly states that elevated LFTs "support the indication for systemic therapy rather than being a reason against it" 2. Psoriasis itself causes systemic inflammation that contributes to liver dysfunction, and treating the psoriasis with appropriate agents can actually improve liver parameters 2, 10.
Before initiating therapy, investigate the cause of elevated LFTs (viral hepatitis, NAFLD/MASLD, alcohol, autoimmune hepatitis) as this may influence drug selection 11.